Beximco Pharmaceuticals (BXP) Competitors GBX 43 -1.00 (-2.27%) As of 04:25 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock BXP vs. GROW, PRSR, PINE, SAGA, DX, ARR, SOHO, MGP, ADVT, and WPCShould you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Molten Ventures (GROW), Prs Reit (PRSR), Pinewood Technologies Group (PINE), Saga (SAGA), DX (Group) (DX), Aurora Investment Trust (ARR), Triple Point Social Housing REIT (SOHO), Medica Group (MGP), AdvancedAdvT (ADVT), and Witan Pacific Investment Trust PLC (WPC.L) (WPC). These companies are all part of the "trading" industry. Beximco Pharmaceuticals vs. Its Competitors Molten Ventures Prs Reit Pinewood Technologies Group Saga DX (Group) Aurora Investment Trust Triple Point Social Housing REIT Medica Group AdvancedAdvT Witan Pacific Investment Trust PLC (WPC.L) Molten Ventures (LON:GROW) and Beximco Pharmaceuticals (LON:BXP) are both small-cap trading companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Do institutionals and insiders hold more shares of GROW or BXP? 57.9% of Molten Ventures shares are held by institutional investors. Comparatively, 1.2% of Beximco Pharmaceuticals shares are held by institutional investors. 1.5% of Molten Ventures shares are held by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer GROW or BXP? Molten Ventures currently has a consensus price target of GBX 580, indicating a potential upside of 46.61%. Given Molten Ventures' stronger consensus rating and higher probable upside, analysts plainly believe Molten Ventures is more favorable than Beximco Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molten Ventures 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Beximco Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, GROW or BXP? Beximco Pharmaceuticals has higher revenue and earnings than Molten Ventures. Molten Ventures is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMolten Ventures£31.70M21.98-£33.58M-£0.00-98,900.00Beximco Pharmaceuticals£46.34B0.00£970.84B£14.253.02 Is GROW or BXP more profitable? Beximco Pharmaceuticals has a net margin of 13.71% compared to Molten Ventures' net margin of -369.09%. Beximco Pharmaceuticals' return on equity of 13.12% beat Molten Ventures' return on equity.Company Net Margins Return on Equity Return on Assets Molten Ventures-369.09% -3.42% -3.46% Beximco Pharmaceuticals 13.71%13.12%6.97% Which has more volatility and risk, GROW or BXP? Molten Ventures has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Beximco Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Does the media favor GROW or BXP? In the previous week, Molten Ventures had 1 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 1 mentions for Molten Ventures and 0 mentions for Beximco Pharmaceuticals. Molten Ventures' average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score. Company Overall Sentiment Molten Ventures Neutral Beximco Pharmaceuticals Neutral SummaryBeximco Pharmaceuticals beats Molten Ventures on 8 of the 15 factors compared between the two stocks. Get Beximco Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BXP vs. The Competition Export to ExcelMetricBeximco PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£191.83M£1.68B£6.08B£2.56BDividend Yield5.95%2.95%5.73%5.32%P/E Ratio3.02112.6184.694,392.87Price / Sales0.001,462.30596.0499,529.17Price / CashN/A10.3737.8627.90Price / Book0.0011.0912.288.16Net Income£970.84B£20.70B£3.32B£5.89B7 Day Performance-2.18%-1.19%1.30%-0.56%1 Month Performance-9.28%2.23%8.49%1.40%1 Year Performance50.61%8.36%72.74%136.87% Beximco Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BXPBeximco PharmaceuticalsN/AGBX 43-2.3%N/A+50.0%£191.83M£46.34B3.025,500Gap DownGROWMolten Ventures2.0371 of 5 starsGBX 408.80+1.5%GBX 580+41.9%+1.6%£720.15M£31.70M-102,200.0020PRSRPrs ReitN/AGBX 112.20+0.2%N/A+9.0%£616.26M£116.05M561.002PINEPinewood Technologies Group3.0628 of 5 starsGBX 396.50-1.1%GBX 700+76.5%+27.6%£453.91M£3.86B635.425,334High Trading VolumeSAGASaga1.4784 of 5 starsGBX 275.50-1.6%GBX 285+3.4%+103.0%£396.60M£615.90M-627.563,682DXDX (Group)N/AN/AN/AN/A£306.77M£471.20M1,185.0020ARRAurora Investment TrustN/AGBX 251-1.2%N/A-0.8%£279.56M£24.22M1,544.62N/APositive NewsSOHOTriple Point Social Housing REITN/AGBX 67.13+0.2%N/A+3.9%£264.13M-£33.30M-592.5010MGPMedica GroupN/AN/AN/AN/A£259.85M£76.98M3,516.671,212ADVTAdvancedAdvTN/AGBX 182.50flatGBX 240+31.5%+41.4%£248.98M£43.27M2,281.25209WPCWitan Pacific Investment Trust PLC (WPC.L)N/AN/AN/AN/A£242.69M£6.74M69.65190 Related Companies and Tools Related Companies Molten Ventures Competitors Prs Reit Competitors Pinewood Technologies Group Competitors Saga Competitors DX (Group) Competitors Aurora Investment Trust Competitors Triple Point Social Housing REIT Competitors Medica Group Competitors AdvancedAdvT Competitors Witan Pacific Investment Trust PLC (WPC.L) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BXP) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beximco Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Beximco Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
